# Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

> **NCT06263153** · PHASE2 · RECRUITING · sponsor: **Yuanquan Yang** · enrollment: 24 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma
- Muscle Invasive Bladder Carcinoma
- Stage II Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Futibatinib
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Radical Cystectomy

## Key facts

- **NCT ID:** NCT06263153
- **Lead sponsor:** Yuanquan Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263153, "Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06263153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*